SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune disease treatments, today announced that an abstract titled “One Year Follow-up Results from a Phase II Trial of the BHT-3009 DNA Vaccine for Multiple Sclerosis,” has been accepted for presentation at the 61st Annual American Academy of Neurology (AAN) meeting, to be held in Seattle, Washington from April 25 through May 2, 2009.
